Home›Diabetes & Endocrinology› SGLT2 inhibitors raise hematocrit by 2.29% and hemoglobin by 0.51 g/dL in type 2 diabetes
SGLT2 inhibitors raise hematocrit by 2.29% and hemoglobin by 0.51 g/dL in type 2 diabetesSGLT2 Inhibitors Linked to Higher Blood Levels in Diabetes Patients
European journal of clinical pharmacologyPublished August 13, 2026Study authors: Ali Elrazi Awadelkarim Hamid, Rabadi Marrita, Aweer Ruba Adel, Subahi Eihab, Abdelmahmuod Elabbass A…PubMed ↗DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Monitor hemoglobin and hematocrit in patients on SGLT2 inhibitors, especially those at risk for erythrocytosis.
This meta-analysis pooled data from 10 studies, including randomized controlled trials (n=171), real-world data (n=9,646), and one observational study (n=100), to evaluate the effect of SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) on hemoglobin and hematocrit in adults with type 2 diabetes. The analysis excluded patients with primary polycythemia, end-stage renal disease, or heart failure. Follow-up ranged from 8 weeks to 24 months.
Pooled results from the RCTs showed a significant increase in hematocrit of +2.29% (95% CI 1.48 to 3.09) and in hemoglobin of +0.51 g/dL (95% CI 0.28 to 0.74). In real-world data, the prevalence of polycythemia increased from 2.4% to 9.7%. These changes appeared reversible after drug discontinuation.
Regarding safety, thrombotic events were reported in 10% of patients with JAK2-unmutated erythrocytosis in the observational study (n=100), but data were limited. The authors noted that larger prospective studies are needed to define the clinical significance of these hematologic changes and the associated thrombotic risk.
Clinicians should be aware of the potential for erythrocytosis and monitor high-risk individuals, but the clinical significance of these changes remains uncertain. The findings do not establish a causal link to thrombotic events, and the overall benefit-risk profile of SGLT2 inhibitors should be considered in the context of their established cardiovascular and renal benefits.
How this fits prior evidence
This meta-analysis extends prior coverage on metabolic effects of diabetes therapies by focusing on hematologic parameters. While earlier items highlighted benefits of tirzepatide on inflammation and lifestyle interventions on diabetes risk, this review addresses a potential adverse effect of SGLT2 inhibitors, complementing the existing evidence on hypoglycemia risk with insulin and polypharmacy. The observed increases in hemoglobin and hematocrit align with known mechanisms but underscore the need for monitoring, consistent with the cautious approach in prior coverage.
A review of several studies looked at how SGLT2 inhibitors, such as empagliflozin and dapagliflozin, affect blood markers in adults with Type 2 Diabetes. The researchers analyzed data from both clinical trials and real-world reports involving thousands of patients.
The analysis found that patients taking these medications showed an increase in hematocrit levels by about 2.29 percent and a rise in hemoglobin levels by 0.51 g/dL. Additionally, the review noted a significant jump in the prevalence of polycythemia among those using SGLT2 inhibitors. These changes in blood markers appeared to be reversible once the medication was stopped.
Because these findings come from a mix of small trials and observational data, it is still unclear how much these changes affect daily health for most people. More large studies are needed to understand the full impact. Patients should talk to their doctor about monitoring these levels if they have specific risks.
What this means for you:
SGLT2 inhibitors are linked to higher hemoglobin and hematocrit, but more research is needed on clinical impacts.
Common questions
What happened to blood levels in patients taking SGLT2 inhibitors?
The study found that patients taking SGLT2 inhibitors showed an increase in hematocrit by 2.29 percent and a rise in hemoglobin by 0.51 g/dL. These changes were consistently linked to the medication and appeared to be reversible after the drug was stopped.
Is there a risk of polycythemia with these medications?
The data showed that the prevalence of polycythemia increased from 2.4% to 9.7% in patients using SGLT2 inhibitors. Because of this link, doctors may want to monitor high-risk individuals more closely.
How certain are these findings regarding blood changes?
The results show a clear link between SGLT2 inhibitors and higher hemoglobin levels. However, because the data for some outcomes is limited, larger studies are still needed to determine the full clinical significance of these changes.
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used in the management of type 2 diabetes mellitus (T2DM) due to their survival benefits. However, these agents are associated with increases in hemoglobin (Hgb) and hematocrit (Hct), raising concern for secondary polycythemia or erythrocytosis and potential thrombotic risk. The clinical significance of these hematologic changes remains unclear.
METHODS: We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines. PubMed, Scopus, and Embase were searched up to February 2026 for studies evaluating the effect of SGLT2 inhibitors on hematologic parameters in adults with T2DM. Patients with primary polycythemia, end-stage renal disease (ESRD), or heart failure were excluded. Primary outcomes were changes in Hgb and Hct. Secondary outcomes included the incidence of erythrocytosis/polycythemia and thrombotic events.
RESULTS: A total of 10 studies met inclusion criteria, comprising randomized and observational studies, with follow-up ranging from 8 weeks to 24 months. SGLT2 inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, were consistently associated with increases in Hgb and Hct. Across three randomized controlled trials, SGLT2 inhibitors significantly increased hematocrit (3 studies, 171 patients, pooled mean difference + 2.29%, 95% CI 1.48 to 3.09) and hemoglobin (3 studies, 171 patients, pooled mean difference + 0.51 g/dL, 95% CI 0.28 to 0.74) compared with placebo. Real-world data (9,646 patients) reported an increase in polycythemia prevalence from 2.4% to 9.7%, with severe cases in 1.4% of patients. Limited data suggested a potential association with thrombotic events, with one observational study of 100 patients with JAK2-unmutated erythrocytosis reporting a 10% event rate. Hematologic changes were observed early after treatment initiation and appeared reversible following drug discontinuation.
CONCLUSIONS: In patients with type 2 diabetes, ESRD, or heart failure, SGLT2 inhibitor use is associated with consistent increases in hemoglobin and hematocrit. Although these effects may contribute to cardiovascular benefit, a subset of patients may develop clinically significant erythrocytosis. Clinicians should be aware of this potential effect and monitor high-risk individuals. Larger prospective studies are needed to better define the clinical significance of these findings.
